BRANFORD, Conn., April 6 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN - News) and TopoTarget A/S announced today that new preclinical data on PXD101, a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, were presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, D.C. PXD101 is currently being evaluated in several Phase II and Phase Ib/II clinical trials for the treatment of multiple myeloma, T-cell lymphomas, ovarian cancer and colorectal cancer. Preclinical results on PXD101 were reported at AACR in two separate poster presentations.
